Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers

NCT ID: NCT02969252

Last Updated: 2018-01-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-07-31

Brief Summary

The objective of the study was to evaluate the pharmacokinetics and the safety of rifamycin SV after single and multiple doses of Rifamycin SV-MMX® 600 mg tablets administered to male and female healthy subjects.

Conditions

Healthy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Open label

Single and multiple dose, open label, pharmacokinetics and safety study

Group Type: OTHER

Rifamycin SV-MMX® 600

Intervention Type: DRUG

Interventions

Rifamycin SV-MMX® 600

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Informed consent: signed written informed consent before inclusion in the study

2. Sex and Age: men and women, 18-55 year old inclusive

3. Body Mass Index: 18.5-30 kgm2 inclusive

4. Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position

5. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study

6. Fertility (women only): women of non-child-bearing potential or in post-menopausal status for at least 1 year.

For all female subjects, pregnancy test result had to be negative at screening and Day -1

Exclusion Criteria

1. ECG 12-leads (supine position): clinically significant abnormalities

2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study

3. Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness

4. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considered could affect the outcome of the study

5. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that could interfere with the aim of the study

6. Medications: medications, including over the counter medications and herbal remedies, for 2 weeks before the start of the study

7. Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval was calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study

8. Blood donation: blood donations for 3 months before this study

9. Drug, alcohol, caffeine, tobacco: history of drug, alcohol (more than 1 drink a day for females and more than 2 drinks a day for males, defined according to the USDA Dietary Guidelines 2010), caffeine (more than 5 cups coffee/tea/day) or tobacco abuse (10 cigarettes a day)

10. Abuse drug test: positive result at the drug test at screening or Day-1

11. Alcohol test: positive alcohol breath test at Day -1

12. Diet: abnormal diets (less than1600 or more than 3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians

13. Pregnancy (females only): positive or missing pregnancy test at screening or Day -1, pregnant or lactating women

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Cosmo Technologies Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

References

Di Stefano AFD, Radicioni MM, Vaccani A, Mazzetti A, Longo LM, Moro L. Pharmacokinetics and Safety of Rifamycin SV after Single and Multiple Doses of MMX(R) Modified Release Tablets in Healthy Male and Female Volunteers. Antibiotics (Basel). 2021 Feb 6;10(2):167. doi: 10.3390/antibiotics10020167.

Reference Type: DERIVED

PMID: 33562091 (View on PubMed)

Other Identifiers

CB-01-11/27

Identifier Type: -

Identifier Source: org_study_id